search button

Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab

  • Authors:
    • Rocco Giannicola
    • Graziella D'Arrigo
    • Cirino Botta
    • Rita Agostino
    • Pietro Del Medico
    • Antonia Consuelo Falzea
    • Vito Barbieri
    • Nicoletta Staropoli
    • Teresa Del Giudice
    • Pierpaolo Pastina
    • Valerio Nardone
    • Marika Monoriti
    • Graziella Calabrese
    • Giovanni Tripepi
    • Luigi Pirtoli
    • Pierfrancesco Tassone
    • Pierosandro Tagliaferri
    • Pierpaolo Correale

  • View Affiliations

  • Published online on: May 16, 2019     https://doi.org/10.3892/mco.2019.1859
  • Pages: 81-90
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Immune‑checkpoint blockade by Nivolumab, a human monoclonal antibody to programmed cell death receptor‑1, is an emerging treatment for metastatic non‑small cell lung cancer (mNSCLC). In order to prolong patient survival, this treatment requires a continuous cross‑priming of tumor derived‑antigens to supply fresh tumor‑specific immune‑effectors; a phenomenon that may also trigger auto‑immune‑related adverse events (irAEs). The present study therefore investigated the prognostic value of multiple autoimmunity‑associated parameters in patients with mNSCLC who were undergoing Nivolumab treatment. This retrospective study included 92 mNSCLC patients who received salvage therapy with Nivolumab (3 mg/kg, biweekly) between September 2015 and June 2018. Log‑rank test, Mantel‑Cox and McPherson analyses were conducted to correlate patient progression‑free survival (PFS) and overall survival (OS) with different parameters including blood cell counts, serum inflammatory markers and auto‑antibodies (AAbs). A median PFS and OS of 10 [inter‑quartile range (IQR): 5.8‑14.2] and 16 [IQR: 6.2‑25.8] months, respectively, were recorded, which did not correlated with age, histology or the number of previous chemotherapy lines. Male gender, the type of therapeutic regimens received prior to Nivolumab, and the occurrence of irAEs were revealed to be positive predictors of prolonged survival (P<0.05). Early detection (within 30 days) of >1AAbs among anti‑nuclear antigens (ANAs), extractable nuclear antigens (ENAs) and anti‑smooth cell antigens (ASMAs) correlated with prolonged PFS [hazard ratio (HR)=0.23; 95% confidence interval (CI): 0.08‑0.62; P=0.004] and OS [HR=0.28 (95% CI: 0.09‑0.88), P=0.03], with the type of treatment received prior to nivolumab (P=0.007) and with the risk of irAEs (P=0.002). In conclusion, increased serum levels of ANA, ENA and/or ASMA are consequential to Nivolumab administration and are predictive of a positive outcome in mNSCLC patients.
View Figures
View References

Related Articles

Journal Cover

July-2019
Volume 11 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Giannicola R, D'Arrigo G, Botta C, Agostino R, Del Medico P, Falzea AC, Barbieri V, Staropoli N, Del Giudice T, Pastina P, Pastina P, et al: Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab. Mol Clin Oncol 11: 81-90, 2019
APA
Giannicola, R., D'Arrigo, G., Botta, C., Agostino, R., Del Medico, P., Falzea, A.C. ... Correale, P. (2019). Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab. Molecular and Clinical Oncology, 11, 81-90. https://doi.org/10.3892/mco.2019.1859
MLA
Giannicola, R., D'Arrigo, G., Botta, C., Agostino, R., Del Medico, P., Falzea, A. C., Barbieri, V., Staropoli, N., Del Giudice, T., Pastina, P., Nardone, V., Monoriti, M., Calabrese, G., Tripepi, G., Pirtoli, L., Tassone, P., Tagliaferri, P., Correale, P."Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab". Molecular and Clinical Oncology 11.1 (2019): 81-90.
Chicago
Giannicola, R., D'Arrigo, G., Botta, C., Agostino, R., Del Medico, P., Falzea, A. C., Barbieri, V., Staropoli, N., Del Giudice, T., Pastina, P., Nardone, V., Monoriti, M., Calabrese, G., Tripepi, G., Pirtoli, L., Tassone, P., Tagliaferri, P., Correale, P."Early blood rise in auto‑antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic‑non‑small cell lung cancer patients treated with PD‑1 immune‑check point blockade by nivolumab". Molecular and Clinical Oncology 11, no. 1 (2019): 81-90. https://doi.org/10.3892/mco.2019.1859